

The logo features the word "DCAT" in blue, "TOP" in orange with an upward-pointing arrow, and "Industry NEWS" in blue.

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*

1. Novartis Makes Changes to Pharmaceutical Division

Novartis has announced changes to its Pharmaceuticals Division by creating two business units: Novartis Pharmaceuticals and Novartis Oncology. These business units will form the Innovative Medicines Division at Novartis. The new structure reflects the importance of oncology to Novartis following the successful integration of the oncology assets acquired from GlaxoSmithKline in 2015. [Read More](#)

2. BMS Completes \$280 Million Expansion at Biologics Facility

Bristol-Myers Squibb has completed a expansion at its Devens, Massachusetts biologics facility. The \$280 million project adds two new buildings: a Biologics Development Building, for designing processes for the early production of investigational medicines, and a Clinical Manufacturing Building, where investigational medicines will be produced to support clinical trials. Both are new capabilities for the Devens site, which had previously focused solely on large-scale, bulk biologics manufacturing. [Read More](#)

3. Biogen Inks \$2 Billion Gene Therapy Deal with Penn

Biogen has announced a broad collaboration and alliance with the University of Pennsylvania to advance gene therapy and gene editing technologies in a deal valued up to \$2 billion. Penn will provide its gene-therapy resources and expertise to develop therapeutic candidates using both existing and newly developed adeno-associated virus gene-delivery vectors and will also aid in developing new manufacturing approaches needed to support commercialization of gene-therapy products. [Read More](#)

4. Sanofi Files Premerger Notification in Move to Acquire Medivation

Sanofi has filed for premerger notification with the US Department of Justice's Antitrust Division and the US Federal Trade Commission regarding its intention to acquire the biopharmaceutical company, Medivation. Sanofi had proposed to acquire Medivation for \$9.3 billion in late April and reiterated its interest again in early May, moves that Medivation has thus far rejected. [Read More](#)

5. Pfizer To Acquire Anacor Pharmaceuticals for \$5.2 Billion

Pfizer has agreed to acquire Anacor Pharmaceuticals, a biopharmaceutical company developing and commercializing small-molecule drugs from a boron chemistry platform, for \$5.2 billion. [Read More](#)

6. Mylan to Acquire Renaissance in \$1 Billion Deal To Boost Topicals Business

Mylan has agreed to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings for \$950 million in cash plus additional contingent payments of up to \$50 million. The business provides Mylan with approximately 25 branded and generic topical products, a pipeline of approximately 25 products, and a US sales and marketing infrastructure targeting dermatologists. [Read More](#)

7. Roche Joins Immuno-Oncology Market with FDA Approval of Atezolizumab

Roche has joined the commercial race in the immuno-oncology market following the granting of

accelerated approval by the FDA for Tecentriq (atezolizumab), a drug to treat bladder cancer. Roche joins the now commercial leaders in the immuno-oncology market: Bristol-Myers Squibb with Opdivo (nivolumab) and Merck & Co. with Keytruda (pembrolizumab). [Read More](#)

8. [J&J, HP Form 3-D Printing Technology Pact for Healthcare](#)

Ushering in a new era, Johnson & Johnson has formed a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. focused on using 3D printing technologies to create better healthcare outcomes. In the near term, the collaboration will focus on the personalization of instrumentation and software for patient-specific healthcare devices. [Read More](#)

9. [EMA Issues Annual Report](#)

The European Medicines Agency has published its 2015 annual report to highlight its key activities and goals. In 2015, the agency recommended marketing authorization for 93 medicines for human use, which included 39 new active substances, and 14 medicines for veterinary use, including seven new active substances. [Read More](#)

10. [US Launches National Microbiome Initiative](#)

The White House Office of Science and Technology Policy, in collaboration with federal agencies and private-sector stakeholders, has launched the National Microbiome Initiative (NMI). The NMI aims to advance understanding of microbiomes for developing applications in healthcare, food production, and environmental restoration. [Read More](#)



*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org